These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Lebovitz HE; Kreider M; Freed MI Diabetes Care; 2002 May; 25(5):815-21. PubMed ID: 11978674 [TBL] [Abstract][Full Text] [Related]
5. Differentiating members of the thiazolidinedione class: a focus on safety. Lebovitz HE Diabetes Metab Res Rev; 2002; 18 Suppl 2():S23-9. PubMed ID: 11921435 [TBL] [Abstract][Full Text] [Related]
6. Hepatotoxicity with thiazolidinediones: is it a class effect? Scheen AJ Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645 [TBL] [Abstract][Full Text] [Related]
7. Pioglitazone. Lawrence JM; Reckless JP Int J Clin Pract; 2000 Nov; 54(9):614-8. PubMed ID: 11220991 [TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones and liver toxicity. Scheen AJ Diabetes Metab; 2001 Jun; 27(3):305-13. PubMed ID: 11431595 [TBL] [Abstract][Full Text] [Related]
9. Differentiating members of the thiazolidinedione class: a focus on efficacy. Goldstein BJ Diabetes Metab Res Rev; 2002; 18 Suppl 2():S16-22. PubMed ID: 11921434 [TBL] [Abstract][Full Text] [Related]
10. [Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)]. Dubois M; Vantyghem MC; Schoonjans K; Pattou F Ann Endocrinol (Paris); 2002 Dec; 63(6 Pt 1):511-23. PubMed ID: 12527853 [TBL] [Abstract][Full Text] [Related]
11. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Diamant M; Heine RJ Drugs; 2003; 63(13):1373-405. PubMed ID: 12825962 [TBL] [Abstract][Full Text] [Related]
12. Pioglitazone and rosiglitazone for diabetes. Drug Ther Bull; 2001 Sep; 39(9):65-8. PubMed ID: 11586802 [TBL] [Abstract][Full Text] [Related]
13. A review of rosiglitazone in type 2 diabetes mellitus. Werner AL; Travaglini MT Pharmacotherapy; 2001 Sep; 21(9):1082-99. PubMed ID: 11560198 [TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes. Cheng-Lai A; Levine A Heart Dis; 2000; 2(4):326-33. PubMed ID: 11728276 [TBL] [Abstract][Full Text] [Related]
15. Are all glitazones the same? Van Gaal L; Scheen AJ Diabetes Metab Res Rev; 2002; 18 Suppl 2():S1-4. PubMed ID: 11921431 [TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Malinowski JM; Bolesta S Clin Ther; 2000 Oct; 22(10):1151-68; discussion 1149-50. PubMed ID: 11110228 [TBL] [Abstract][Full Text] [Related]
17. Troglitazone in type II diabetes mellitus. Sparano N; Seaton TL Pharmacotherapy; 1998; 18(3):539-48. PubMed ID: 9620105 [TBL] [Abstract][Full Text] [Related]
18. Glitazones: clinical effects and molecular mechanisms. Stumvoll M; Häring HU Ann Med; 2002; 34(3):217-24. PubMed ID: 12173692 [TBL] [Abstract][Full Text] [Related]
19. [The thiazolidinedione derivates: a new class of oral blood glucose lowering agents]. Jazet IM; Meinders AE Ned Tijdschr Geneeskd; 2001 Aug; 145(32):1541-7. PubMed ID: 11525086 [TBL] [Abstract][Full Text] [Related]
20. [Evaluation of a thiazolidinedione compound as a new antidiabetic drug]. Toyota T Nihon Rinsho; 2001 Nov; 59(11):2211-8. PubMed ID: 11712410 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]